Kolexia
Villa Julie Oncologie radiothérapie
Villa Julie
Oncologie radiothérapie
Hôpital Nord Grenoble
La Tronche, France
57 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Métastase tumorale Carcinome épidermoïde Carcinome pulmonaire à petites cellules Carcinomes Carcinome épidermoïde de la tête et du cou Tumeurs de la tête et du cou Carcinome pulmonaire non à petites cellules Tumeurs du cerveau

Collaborateurs

Voir plus
Toffart Anne-Claire
Toffart Anne-Claire
Hôpital Nord Grenoble, La Tronche, France
Moro-Sibilot Denis
Moro-Sibilot Denis
Hôpital Nord Grenoble, La Tronche, France
Verry Camille
Verry Camille
Hôpital Nord Grenoble, La Tronche, France
Iriart Carole
Iriart Carole
Hôpital Nord Grenoble, La Tronche, France

Industries

Voir plus
B3TSI
8 collaboration(s)
Dernière en 2023
MSD
7 collaboration(s)
Dernière en 2022
Inter-View Partners France
4 collaboration(s)
Dernière en 2023
AstraZeneca
4 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Lung cancer, comorbidities, and medication: the infernal trio.
Frontiers in pharmacology   21 février 2024
NANORAD2: Radiotherapy of Multiple Brain Metastases Using AGuIX® Gadolinium-chelated Polysiloxane Based Nanoparticles: a Prospective Randomized Phase II Clinical Trial.
Essai Clinique (CHU Grenoble)   16 août 2023
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
European journal of cancer (Oxford, England : 1990)   09 janvier 2023
LBA33 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial: A Phase I/II Randomized Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Antitumor Activity of Debio 1143 Combined With Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Essai Clinique (Debiopharm)   22 juin 2022
Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   05 mars 2022
Survival of clinical stage III NSCLC according to therapeutic strategy: Relevance of the tumor board decision in the era of immunotherapy.
Cancer treatment and research communications   04 janvier 2022
ETOILE: Transnational Randomized Study Comparing Carbon Ions Therapy Versus Conventional Radiotherapy - Including Protontherapy - for the Treatment of Radioresistant Tumors
Essai Clinique (Hospices Civils de Lyon)   01 septembre 2021
Histosurgical mapping of endoscopic endonasal surgery of sinonasal tumours to improve radiotherapy guidance.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   24 juin 2021
Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial).
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   05 mai 2021